Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Bluebird bio stock slides for second day on buyout news
Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.
TipRanks on MSN6h
NSM Insurance to sell U.S. commercial insurance division to New Mountain Capital
NSM Insurance Group announced it has signed a definitive agreement to sell its U.S. commercial insurance division to New Mountain Capital, a ...
Bluebird Bio price target lowered to $5 from $40 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...
pharmaphorum9h
Troubled gene therapy player bluebird sold for a song
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
The Pharma Letter9h
The week in pharma: action, reaction and insight – week to February 21
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
GEN23h
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...